Depression in Parkinson’s Disease

Parkinson's Disease

Volumn , Issue , 2004, Pages 329-338

  Wengel, Steven P ^a   Bohac, Daryl ^a   Burke, William J ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84964719613     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203508596-41     Document Type: Chapter

References (57)

1. Cummings, J. L., Depression and Parkinson’s disease: A review, Am. J. Psychiatry, 149(4):443–54, April, 1992.
2. Tandberg, E., Larsen, J. P., Aarsland, D., Cummings, J. L., The occurrence of depression in Parkinson’s disease. A community-based study, Arch. Neurol., 53(2):175–9, February, 1996.
3. American Psychiatri Association, Diagnostic and statistical manual of mental disorder, 3rd ed., Washington, DC, American Psychiatric Association, 1980.
4. Montgomery and Asberg, M., A new depression scale designed to be sensitive to change, British Journal of Psychiatry, 134:382–9, 1979.
5. Folstein, M. F., Folstein, S. E., McHugh, P. R., “Mini-Mental State: A practical method of grading the cognitive state of patients for the clinician,” J. of Psychiatric Research, 12:189–98, 1975.
6. Goldberg, D. P., William, P., A user’s guide to the General Health Questionnaire, Windsor, NFER-NELSON, 1988.
7. Hantz, P., Caradoc-Davies, G., Caradoc-Davies, T., Weatherall, M., Dixon, G., Depression in Parkinson’s disease, Am. J. Psychiatry, 151(7):1010–4, July, 1994.
8. American Psychiatric Association, Diagnostic and statistical manual of mental disorder, 4th ed., Washington, DC,1994.
9. Leentjens, A. F. G., Marinus, J., Van Hilten, J. J., Lousberg, R., Verhey, F. R. J., The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson’s disease: A discriminant analytic approach, J. Neuropsychiatry Clin. Neurosci., 15:(1):74–77, 2003.
10. Hamilton, M., A rating scale for depression, Journal of Neurology, Neurosurgery and Psychiatry, 23:56–62, 1960.
11. Leentjens, A. F. G., Lousber, R., Verhey, F. J. R., Markers for depression in Parkinson’s disease, Acta Psychiatr. Scand., 106:196–201, 2002.
12. Starkstein, S. E., Berthier, M. L., Bolduc, P. L., Preziosi, T. J., Robinson, R. G., Depression in patients with early versus late onset Parkinson’s disease, Neurology, 39:1441–1445, 1989.
13. Gotham, A. M., Brown, R. G., Marsden, C. D., Depression in Parkinson’s disease: A quantitative and qualitative analysis, J. Of Neurology, Neurosurgery Psychiatry, 49:381–389, 1986.
14. Brown, R. C., MacCarthy, B., Psychiatric morbidity in patients with Parkinson’s disease, Psychol. Med., 20:77–87, 1990.
15. Huber, S. J., Paulson, G. W., Shuttleworth, E. C., Depression in Parkinson’s disease, Neuropsychiatry Neuropsychol. Behav. Neurol., 1:47–51, 1988.
16. Jankovic, J., McDermott, M., Carter, J. et al., Parkinson Study Group. Variable expression of Parkinson’s disease: A baseline analysis of the DATATOP cohort, Neurology, 40:1529–1534, 1990.
17. Brown, G. L., Wilson, W. P., Parkinsonism and depression, South Med. J., 65:540–545, 1972.
18. Starkstein, S. E., Preziosi, T. J., Bolduc, P. L., Robinson, R. G., Depression in Parkinson’s disease, J. Nerv. Ment. Dis., 178(1):27–31, January, 1990.
19. Celesia, G. G., Wanamaker, W. M., Psychiatric disturbances in Parkinson’s disease.
20. Brown, R., Jahanshahi, M., Depression in Parkinson’s disease: A psychosocial viewpoint, Adv. Neurol., 65:61–84, 1995.
21. MacCarthy, B., Brown, R. G., Psychosocial factors in Parkinson’s disease, Br. J. Clin. Psychol., 28:41–52, 1989.
22. Oertel, W. H., Hoglinger, G. U., Caraceni, T., Girotti, F., Eichhorn, T., Spottke, A. E., Krieg, J. C. et al., Depression in Parkinson’s disease, Advances in Neurology, 86:373–383, 2001.
23. Zarow, C., Lyness, S. A., Mortimer, J. A., Chui, H. C., Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson Diseases, Arch. Neurol., 60:337–341, 2003.
24. Price, K. S., Farley, I. J., Hornykiewicz, O., Neurochemistry of Parkinson’s disease: Relation between striatal and limbic dopamine, Adv. Biochem. Psychopharmacol., 19:293–300, 1978.
25. Javoy-Agid, F., Agid, Y., Is the mesocortical dopaminergic system involved in Parkinson’s disease? Neurology, 30:1326–1330, 1980.
26. Baxter, L. R., Schwartz, J. M., Phelps, M. E. et al., Reduction of prefrontal cortex glucose metabolism common in three types of depression, Arch. Gen. Psychiatry, 46:243–250, 1989.
27. Gonera, vant’t Hof M., Berger, H. J., van Weel, C., Horstink, M. W., Symptoms and duration of the prodromal phase in Parkinson’s disease, Mov. Disorder, 12:871–876, 1997.
28. Nilsson, F. M., Kessing, L. V., Bolwig, T. C., Increased risk of developing Parkinson’s disease for patients with major affective disorder-a register study, Acta Psychiatr. Scand., 104:380–386, 2001.
29. Krishnan, K. R., Delong, M., Kraemer, H., Carney, R., Spiegel, D. et al., Comorbidity of depression with other medical diseases in the elderly, Biol. Psychiatry, 52:559–588, 2002.
30. Nilsson, F. M., Kessing, L. V., Sorensen, T. M., Anderson, P. K., Bolwig, T. G., Major depressive disorder in Parkinson’s disease: A register-based study, Acta Psychiatr. Scand., 106:202–211, 2002.
31. desRosiers, G., Primary or depressive dementia: Psychometric assessment, Clinical Psychology, 12:307–343, 1992.
32. LaRue, A., Aging and Neuropsychological Assessment, Plenum, New York, 259–289, 1992.
33. Rosenstein, L. D., Differential diagnosis of the major progressive dementias and depression in middle and late adulthood: A summary of the literature of the early 1990s, Neuropsychology Review, 8:109–167, 1998.
34. Mahurin, R. K., Feher, E. P., Nance, M. L., Levy, J. K., Priozzolo, F. J., Cognition in Parkinson’s disease and related disorders. In Parks, R. W., Zec, R. F., Wilson, R. S., Eds., Neuropsychology of Alzheimer’s Disease and Other Dementias. Oxford University Press, New York, 308–349, 1993.
35. Levin, B. E., Katzen, H. L., Early cognitive changes and nondementing behavioral abnormalities in Parkinson’s disease, in Weiner, W. J., Lang, A. E., Eds., Advances in Neurology, Vol. 65, Raven Press, New York, 85–95, 1995.
36. Bondi, M. W., Kaszniak, A. W., Bayles, K. A., Vance, K. T., Contributions of frontal system dysfunction to memory and perceptual abilities in Parkinson’s disease, Neuropsychology, 7:89–102, 1993.
37. Norman, S., Troster, A. I., Fields, J. A., Brooks, R., Effects of depression and Parkinson’s disease on cognitive functioning, J. of Neuropsychiatry and Clinical Neurosciences, 14:31–36, 2002.
38. Factor, S. A., Molho, E. S., Podskalny, G. D., Brown, D., Parkinson’s disease: Drug-induced psychiatric states, in Behavioral Neurology of Movement Disorders, Weiner, W. J., and Lang, A. E., eds., Advances in Neurology, Vol. 65, Raven Press, Ltd., New York, 1995.
39. Bejjani, B. P., Damier, P., Arnulf, I., Thivard, L., Bonnet, A. M. et al., Transient acute depression induced by highfrequency deep-brain stimulation, NEJM, 340(19): 1476–1480, 1999.
40. Alexopoulos, G., Kiosses, D., Klimstra, S., Kalayam, B., Bruce, M., Clinical presentation of the “depressionexecutive dysfunction syndrome” of late life, Am. J. Geriatr. Psychiatry, 10(1):98–106, 2002.
41. Berney, A., Vingerhoets, F., Perrin, A., Phil, L., Guex, P., Villemure, J. G., Burkhard, P. R., Benkelfat, C., Ghika, J., Effect on mood of subthalamic DBS for Parkinson’s disease: A consecutive series of 24 patients, Neurology, 59:1427–1429, 2002.
42. Kulisevsky, J., Berthier, M. L., Gironell, A., Pascual-Sedano, B., Molet, J., Pares, P., Mania following deep brain stimulation for Parkinson’s disease, Neurology, 59:1421–1424, 2002.
43. Mendis, T., Suchowersky, O., Lang, A., Gauthier, S., Management of Parkinson’s disease: A review of current and new therapies, Can. J. Neurol. Sci., 26:89–103, 1999.
44. Lieberman, A., Managing the neuropsychiatric symptoms of Parkinson’s disease, Neurology, 50:S33–S38, 1998.
45. Poewe, W., Seppi, K., Treatment options for depression and psychosis in Parkinson’s disease, J. Neurol., 248:12–21, 2001.
46. Aarsland, D., Cummings, J. L., Depression in Parkinson’s disease, Acta Psychiatri. Scand., 106:161–162, 2002.
47. Ceravolo, R., Nuti, A., Piccinni, A., Dell’Agnello, G., Bellini, G., Gambaccini, G., Dell’Osso, L., Juri, L., Bonuccelli, U., Paroxetine in Parkinson’s disease: Effects on motor and depressive symptoms, Neurology, 55:1216–1218, 2000.
48. Gony, M., Lapeyre-Mestre, M., Montastruc, J. L., Risk of serious extrapyramidal symptoms in patients with Parkinson’s disease receiving antidepressant drugs: A pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs, Clin. Neuropharmacol., 26(3):142–5, 2003.
49. Ritter, J. L., Alexander, B., Retrospective study ofselegiline-antidepressant drug interactions and a review of the literature, Ann. Clin. Psychiatry, 9:7–13, 1997.
50. Waters, C. H., Fluoxetine and selegiline—lack of significant interaction, Can. J. Neurol. Sci., 21(3):259–61, 1994.
51. Ereshefsky, L., Alfaro, C. L., Lam, Y. W., Treating depression: Potential drug interactions, Psychiatric Annals, 27:244–258, 1991.
52. Onofrj, M., Luciano, A. L., Thomas, A., Iacono, D., D’Andreamatteo, G., Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism, Neurology, 60: 113–115, 2003.
53. Weintraub, D., Nortriptyline toxicity secondary to interaction with bupropion sustained-release, Depress Anxiety, 13:50–52 2001.
54. Richard, I. H., Depression in Parkinson’s disease, Curr. Treat. Options. Neurol., 2(3):263–274, 2000.
55. Okun, M. S., McDonald, W. M., DeLong, M. R., Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: A common unrecognized comorbidity, Arch. Neurol., 59:807–811, 2002.
56. Burke, W. J., Peterson, J., Rubin, E. H., Electroconvulsive therapy in the treatment of combined depression and Parkinson’s disease. Psychosomatics, 29:341–346, 1988.
57. Wengel, S. P., Burke, W. J., Pfeiffer, R. F., Roccaforte WH, Paige SR. Maintenance electroconvulsive therapy for intractable Parkinson’s disease, Am. J. Geriatr. Psychiatry, 6:263–269, 1998.